

What is claimed is:

1. A method for eliminating a target cell or antigen from the circulatory system of a subject comprising, administering to the subject a complex comprising a first portion which specifically binds Fc α RI expressed on liver Kupffer cells, or which specifically binds monomeric IgA or the Fc region thereof, linked to a second portion which specifically binds the target cell or antigen.
2. The method of claim 1, wherein the first portion of the complex binds a site on Fc α R that is distinct from the binding site for IgA, so that binding of the complex is not blocked by IgA.
3. The method of claim 1, wherein the first portion of the complex comprises monomeric IgA or the Fc region thereof.
4. The method of claim 1, wherein the first portion of the complex comprises an antibody or antibody fragment which specifically binds Fc α RI.
5. The method of claim 4, wherein the antibody is a human or humanized antibody.
6. The method of claim 1, wherein the second portion of the complex comprises an antibody or an antibody fragment thereof which specifically binds the target cell or antigen.
7. The method of claim 1, wherein the target cell is a cancer cell.
8. The method of claim 1, wherein the target antigen is selected from the group consisting of a bacteria, a virus, and a fungus.
9. The method of claim 1, further comprising the step of administering to the subject a cytokine which increases expression of Fc α RI on Kupffer cells.
10. The method of claim 9, wherein the cytokine is selected from the group consisting of GM-CSF, IL-6, IL-1 β , IL-8, and TNF- α .

11. The method of claim 1, wherein the complex is administered by injection.

12. The method of claim 11, wherein the complex is administered
5 intravenously.

13. A method for treating liver cancer in a subject comprising, administering to the subject a complex comprising a portion which specifically binds Fc α RI expressed on liver cells, or which specifically binds monomeric IgA or the Fc
10 region thereof, linked to a cytotoxin.

14. The method of claim 13, wherein the portion which binds Fc α RI comprises monomeric IgA or the Fc region thereof.

15. The method of claim 13, wherein the portion that binds Fc α RI comprises an antibody or antibody fragment.

16. The method of claim 15, wherein the antibody is a human or humanized antibody.
20

17. The method of claim 11, further comprising administering to the subject a cytokine which increases expression of Fc α RI on the liver cells.

18. The method of claim 17, wherein the cytokine is selected from the
25 group consisting of GM-CSF, IL-6, IL-1 β , IL-8, and TNF- α .

19. A method for treating or preventing septicemia in a subject comprising administering to the subject a complex comprising a portion which specifically binds Fc α RI expressed on liver cells, or which specifically binds
30 monomeric IgA or the Fc region thereof, linked to a cytotoxin.

20. The method of claim 19, wherein the portion which Fc α RI comprises monomeric IgA or the Fc region thereof.

21. The method of claim 19, wherein the portion that binds Fc α RI comprises an antibody or antibody fragment.
35

- | Variable | Mean (SD) | | p-value |
|--------------------------------------|-------------|-------------|---------|
| | Control | Case | |
| Age (years) | 45.2 (12.5) | 46.8 (13.1) | 0.85 |
| Gender (male/female) | 15/15 | 16/14 | 0.92 |
| Duration of illness (years) | 12.3 (8.7) | 11.5 (9.2) | 0.78 |
| Family history of AD | 8/15 | 10/16 | 0.65 |
| Education (years) | 12.1 (1.5) | 11.9 (1.6) | 0.91 |
| Occupational history | 15/15 | 16/14 | 0.88 |
| Alcohol consumption (g/day) | 15.2 (10.5) | 14.8 (11.2) | 0.95 |
| Tobacco consumption (cigarettes/day) | 12.5 (8.3) | 11.9 (9.1) | 0.82 |
| Medication use | 15/15 | 16/14 | 0.90 |
| Comorbidities | 15/15 | 16/14 | 0.87 |
| Genetic testing results | 15/15 | 16/14 | 0.93 |
| Neuroimaging findings | 15/15 | 16/14 | 0.89 |
| Neuropsychological test scores | 15/15 | 16/14 | 0.86 |
| Pathological findings | 15/15 | 16/14 | 0.94 |
| Outcome measures | 15/15 | 16/14 | 0.91 |